4 results
To study whether a novel plaster (Rapydan) is more successfull in diminishing pain/ discomfort than the usual plaster (EMLA).
Primary objective• To determine the optimal dose of IMU-838 to induce symptomatic remission (based on stool frequency [SF] and abdominal pain [AP], as assessed in the Crohn*s Disease Activity Index [CDAI] patient reported outcome [PRO]-2) in…
The project*s overarching aim is to diminish respiratory disease burden in moderate-late preterm born infants in their first year of life.We have formulated the following specific aims: 1. Determine whether bacterial lysates reduce the number and/or…
To determine the optimal dose of IMU-838 to induce symptomatic remission and endoscopic healing in patients with moderate-to-severe ulcerative colitis (UC)